Study S000597

Liraglutide in Type 1 Diabetes. A Randomised, Double-blind, Placebo Controlled Study of the Effect of Liraglutide as an Additional Treatment to Insulin on HbA1c, Body Weight and Hypoglycaemia in Poorly Regulated Type 1 Diabetes Patients

ClinicalTrials.gov record

Registration

Registration: NCT01612468
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: TRIPLE
Status: COMPLETED
Enrollment: 100
Start: 2012-06
Primary completion: 2015-02
Lead sponsor: Steno Diabetes Center Copenhagen
Conditions: Diabetes Mellitus, Type 1; Overweight
Interventions: DRUG:Liraglutide; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

Change in HbA1c [24 week]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0046954	734-P: The Effect of Adjunctive Therapy with Liraglutide on Insulin Sensitivity in Overweight Persons with Type 1 Diabetes Thomas Fremming Dejgaard, Diabetes	2022	Randomized trial	DOI	cites ClinicalTrials.gov:NCT01612468
R0023437	Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Dejgaard TF, The lancet. Diabetes & endocrinology	2016	Randomized trial	PMID 26656289 DOI	cites ClinicalTrials.gov:NCT01612468; registry reference DERIVED:26656289
R0011465	Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study. Dejgaard TF, BMJ open	2015	Protocol	PMID 25838513 DOI	cites ClinicalTrials.gov:NCT01612468; registry reference DERIVED:25838513